BR112013020500A2 - anticorpo isolado, recombinante ou purificado - Google Patents

anticorpo isolado, recombinante ou purificado

Info

Publication number
BR112013020500A2
BR112013020500A2 BR112013020500A BR112013020500A BR112013020500A2 BR 112013020500 A2 BR112013020500 A2 BR 112013020500A2 BR 112013020500 A BR112013020500 A BR 112013020500A BR 112013020500 A BR112013020500 A BR 112013020500A BR 112013020500 A2 BR112013020500 A2 BR 112013020500A2
Authority
BR
Brazil
Prior art keywords
recombinant
isolated
purified antibody
antibody
compositions
Prior art date
Application number
BR112013020500A
Other languages
English (en)
Other versions
BR112013020500A8 (pt
Inventor
Benoit Grellier
Christine Thioudellet
Hélène Haegel
Jean-Baptiste Marchand
Michel Geist
Original Assignee
Transgène S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgène S A filed Critical Transgène S A
Publication of BR112013020500A2 publication Critical patent/BR112013020500A2/pt
Publication of BR112013020500A8 publication Critical patent/BR112013020500A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

anticorpo isolado, recombinante ou purificado a presente invenção fornece anticorpos específicos para o cfs-1r, composições que compreendem o dito anticorpo e métodos de tratamento que usam tais composições.
BR112013020500A 2011-02-14 2012-02-07 anticorpo isolado, recombinante ou purificado BR112013020500A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/026,944 US8470977B2 (en) 2008-03-14 2011-02-14 Antibody against the CSF-1R
PCT/EP2012/052043 WO2012110360A1 (en) 2011-02-14 2012-02-07 Antibody against the csf-1r

Publications (2)

Publication Number Publication Date
BR112013020500A2 true BR112013020500A2 (pt) 2016-10-18
BR112013020500A8 BR112013020500A8 (pt) 2018-01-09

Family

ID=45808764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013020500A BR112013020500A8 (pt) 2011-02-14 2012-02-07 anticorpo isolado, recombinante ou purificado

Country Status (18)

Country Link
US (3) US8470977B2 (pt)
EP (1) EP2675826B1 (pt)
JP (1) JP5996558B2 (pt)
KR (1) KR101920946B1 (pt)
CN (2) CN104140467B (pt)
AU (1) AU2012217303B2 (pt)
BR (1) BR112013020500A8 (pt)
CA (1) CA2825243A1 (pt)
DK (1) DK2675826T3 (pt)
ES (1) ES2654551T3 (pt)
HK (1) HK1203976A1 (pt)
HU (1) HUE035617T2 (pt)
IL (1) IL227078A (pt)
MX (1) MX347020B (pt)
RU (1) RU2621859C2 (pt)
SG (1) SG191899A1 (pt)
WO (1) WO2012110360A1 (pt)
ZA (1) ZA201306869B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009224955B2 (en) 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN102791738B (zh) 2009-12-10 2015-10-07 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
TWI595008B (zh) 2010-05-04 2017-08-11 戊瑞治療有限公司 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
SG11201401639QA (en) 2011-10-21 2014-05-29 Transgene Sa Modulation of macrophage activation
EA201700111A1 (ru) 2011-10-28 2018-02-28 Тева Фармасьютикал Австралия Пти Лтд Полипептидные конструкции и их применение
KR20140113683A (ko) 2011-12-15 2014-09-24 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG11201501413YA (en) 2012-08-31 2015-03-30 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9676859B2 (en) 2012-11-09 2017-06-13 Transgene Sa In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody
WO2014167088A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN106795222A (zh) 2014-06-23 2017-05-31 戊瑞治疗有限公司 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法
DK3169341T3 (da) 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
RU2705780C2 (ru) 2014-07-16 2019-11-11 Трансген Са Комбинация онколитического вируса с модуляторами иммунологических контрольных точек
ES2851390T3 (es) 2014-10-29 2021-09-06 Five Prime Therapeutics Inc Terapia de combinación para el cáncer
KR20170096187A (ko) 2014-12-22 2017-08-23 파이브 프라임 테라퓨틱스, 인크. Pvns를 치료하기 위한 항-csf1r 항체
RS61531B1 (sr) 2015-04-13 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
WO2016175236A1 (ja) * 2015-04-28 2016-11-03 田辺三菱製薬株式会社 ＲＧＭａ結合タンパク質及びその使用
EA039951B1 (ru) * 2015-05-27 2022-03-31 Юсб Биофарма Спрл Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
EP3349794A4 (en) * 2015-09-16 2019-07-31 Ablexis, LLC ANTI-CD115 ANTIBODIES
US10844395B2 (en) 2016-06-16 2020-11-24 Farmhannong Co., Ltd. Methods and compositions for conferring and/or enhancing herbicide tolerance using protoporphyrinogen oxidase or variant thereof
MX2018016364A (es) 2016-06-20 2019-11-28 Kymab Ltd Anticuerpos anti-pd-l1.
EP3486254A4 (en) * 2016-07-05 2019-12-18 Ibentrus, Inc. COMPOSITION FOR THE TREATMENT OF CANCER FOR INHIBITING TUMOR ANGIOGENESIS, CONTAINING A VEGF DEEP-BLOCKING AGENT, AND METHOD FOR PREPARING THE SAME
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
EP3522925A4 (en) * 2017-01-10 2020-06-10 National Yang-Ming University METHOD FOR TREATING CANCER METASTASES AND COMPOSITION THEREOF
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
US20220064310A1 (en) * 2018-12-13 2022-03-03 Development Center For Biotechnology Anti-human csf-1r antibody and uses thereof
AU2020283742A1 (en) 2019-05-24 2021-09-16 Elixiron Immunotherapeutics (hong Kong) Limited Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
RU2751249C1 (ru) * 2020-10-28 2021-07-12 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с csf-1r
CN114907489A (zh) * 2022-04-24 2022-08-16 首都医科大学附属北京天坛医院 一种可诱导嵌合抗原受体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US245471A (en) * 1881-08-09 fabwell
US59113A (en) * 1866-10-23 Improvement in horse-rakes
US317403A (en) * 1885-05-05 Seal-lock for car-doors
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0517367A (ja) 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
DE69426841T2 (de) 1993-02-16 2001-09-06 Onyx Pharma Inc Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001030381A2 (de) 1999-10-28 2001-05-03 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren
EP1463757A2 (fr) 2002-01-03 2004-10-06 Transgene Antisens diriges contre le csf-1 humain
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP1704166B1 (en) 2004-01-07 2015-04-29 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
ATE504599T1 (de) 2004-01-16 2011-04-15 Regeneron Pharma Zur aktivierung von rezeptoren fähige fusionspolypeptide
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
ES2650224T3 (es) * 2007-08-21 2018-01-17 Amgen, Inc. Proteínas de unión al antígeno C-FMS humano
AU2009224955B2 (en) * 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
SG11201401639QA (en) * 2011-10-21 2014-05-29 Transgene Sa Modulation of macrophage activation
US9676859B2 (en) * 2012-11-09 2017-06-13 Transgene Sa In vitro generation of dendritic cells by exposure to an anti-CSF1-R antibody

Also Published As

Publication number Publication date
CN104140467B (zh) 2017-05-31
AU2012217303A1 (en) 2013-07-11
KR20140032992A (ko) 2014-03-17
US9428584B2 (en) 2016-08-30
JP5996558B2 (ja) 2016-09-21
NZ612038A (en) 2014-09-26
HUE035617T2 (en) 2018-05-28
US8470977B2 (en) 2013-06-25
EP2675826A1 (en) 2013-12-25
AU2012217303B2 (en) 2016-10-20
US20110178278A1 (en) 2011-07-21
EP2675826B1 (en) 2017-11-01
RU2621859C2 (ru) 2017-06-07
JP2014506572A (ja) 2014-03-17
KR101920946B1 (ko) 2018-11-21
SG191899A1 (en) 2013-08-30
CA2825243A1 (en) 2012-08-23
DK2675826T3 (en) 2018-01-22
RU2013141956A (ru) 2015-03-27
US20170002081A1 (en) 2017-01-05
WO2012110360A1 (en) 2012-08-23
ES2654551T3 (es) 2018-02-14
ZA201306869B (en) 2014-05-28
IL227078A (en) 2017-06-29
HK1203976A1 (en) 2015-11-06
MX347020B (es) 2017-04-06
CN104140467A (zh) 2014-11-12
CN103476794B (zh) 2017-05-03
BR112013020500A8 (pt) 2018-01-09
MX2013009362A (es) 2014-04-25
CN103476794A (zh) 2013-12-25
US9982055B2 (en) 2018-05-29
US20130289250A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
CY1122278T1 (el) Αντι il-36r αντισωματα
CO2017012286A2 (es) Anticuerpos anti-cd40
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EP3702372A3 (en) Anti-cd40 human antibodies
CR20120577A (es) Anticuerpos hacia gdf8 humano
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
EA201201016A1 (ru) Антидоты антикоагулянтов
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
EA201491151A1 (ru) Соединения, ингибирующие металлоферменты
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
IN2014DN05885A (pt)
BR112014009866A2 (pt) formulações de anticorpos e métodos
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EP3492101A3 (en) Agents for influenza neutralization
BR112017022073A2 (pt) método para purificação de proteína

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2708 DE 29-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.